Replies to post #169323 on Biotech Values

[oc631]

NVS-ENTA HCV program in GT2/3?



Here's a GT2/GT3 dose escalation study of Alisporivir in combination with Riba. The abstract I posted appears to hint at a NS5A inhibitor combination.




http://clinicaltrials.gov/ct2/show/NCT01970904?term=Alisporivir&rank=5